Elcin Barker Ergun, Menarini CEO (Menarini)
Menarini bags Stemline and a rare disease drug in $677M buyout. But will a better offer follow?
Italy’s Menarini Group has struck a deal to buy Stemline Therapeutics $STML for $677 million, adding an FDA-approved drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
